PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Clinical Distribution”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 37 records · Page 2Linked to original sources
PubMed2026

Four-year surveillance of major Gram-negative pathogens in a Saudi tertiary hospital: clinical distribution, comorbidity profiles, and antimicrobial resistance.

PURPOSE: To describe four-year diagnostic-distribution, burden, and antimicrobial-resistances of major Enterobacterales and Pseudomonas aeruginosa in a tertiary-care surveillance framework. PATIENTS AND METHODS: We retrospectively studied first non-duplicate-isolate per/patient/organism between 2022-2025 at a Saudi tertiary-care. Diagnostics used automated-platforms with GeneXpert-Carba-R employed parallel to cultures. Susceptibility interpretations used CLSI-breakpoints relevant to test-year. Annual-trends were assessed with grouped-binomial logistic-regression, and Benjamini-Hochberg false-discovery-rate correction was applied within prespecified analysis. RESULTS: Among 1,857 isolates, Klebsiella pneumoniae was most frequent (36.2%), followed by P.&#xa0;aeruginosa (33.4%), Escherichia coli (17.9%), and Enterobacter cloacae (12.3%). Mean patient age was 64.8&#x2009;years, 51.3% isolates were from intensive-care, 37.4% from urine, and 80.8% records had comorbidity. K.&#xa0;pneumoniae showed overall ESBL (76.6%), CRE (59.9%), MDR (69.3%), panel-defined XDR (64.7%), and panel-defined PDR (15.2%) frequencies. Enterobacterales ESBL-positivity increased (58.1% to 76.8%;q&#x2009;<0.001), whereas meropenem non-susceptibility decreased (52.6% to 33.2%;q&#x2009;<0.001). In P.&#xa0;aeruginosa, ceftazidime non-susceptibility increased (55.2% to 78.6%;q&#x2009;<0.001), meropenem decreased (46.8% to 32.9%;q&#x2009;=&#x2009;0.031), and tobramycin increased (22.2% to 45.7%;q&#x2009;=&#x2009;0.030). Crude-comorbidity differences remained insignificant after false-discovery-rate correction. CONCLUSION: We show a persistent species-specific Gram-negative resistance burden, led by K.&#xa0;pneumoniae and accompanied by substantial P.&#xa0;aeruginosa non-susceptibility. This supports organism-specific detections, antibiograms and continued multicenter-surveillance linked to antimicrobial exposure, genomic-data, and patient outcomes.

ESBL↗
PubMed1994

Infarcts in the anterior choroidal artery territory. Anatomical distribution, clinical syndromes, presumed pathogenesis and early outcome.

From a prospective registry of all consecutive patients with a supratentorial ischaemic stroke, those with a compatible CT lesion were selected to study topographical relationship, clinical syndrome, vascular risk factors, signs of large-vessel disease or cardiogenic embolism, and mortality in cases with an infarct in the anterior choroidal artery (AChA) territory in comparison with other infarct subtypes. First we identified the area supplied by the AChA: in accordance with the consensus in the literature the posterior two-thirds of the posterior leg of the internal capsule was considered as certain AChA territory. After reviewing CT scans, all presumed small deep AChA territory infarcts were displayed in a schematic composite picture of super-imposed areas of infarction in different shades of grey. Infarcts that were located largely outside the generally included territory were presumed to belong to a different vascular territory. Thus, 77 small deep infarcts were considered to be located within, and 83 outside the AChA territory. Twenty-nine AChA infarcts extended from the internal capsule upwards into the posterior paraventricular corona radiata region. Furthermore, the composite representation of 26 infarcts restricted to the posterior part of the paraventricular corona radiata region showed almost complete overlap with the area occupied by AChA infarcts that extended upwards. We therefore concluded that the posterior paraventricular area is most likely supplied by the AChA. The frequency of a clinical lacunar or a cortical syndrome did not differ between small deep AChA and remaining small deep infarcts. Comparison of vascular risk factors by way of multivariate regression analysis only showed that a significant carotid stenosis was more frequent (adjusted odds ratio 8.87; 95% confidence interval 1.44-54.50), and a cardioembolic source was less frequent (odds ratio 0.24; 95% confidence interval 0.07-0.92) in AChA infarcts than in the other small deep infarcts. Carotid stenosis and cardiac embolism were less frequent in AChA infarcts than in superficial infarcts (odds ratio 0.33, 0.23, respectively; 95% confidence interval 0.15-0.74, 0.09-0.52, respectively). One month and one year mortality were lower in small deep infarcts compared with superficial infarcts, but most favourable in the AChA group. However, this was probably related to younger age in the AChA patients. Larger AChA infarcts were infrequent in our series; six of such cases did not differ in any respect from superficial infarcts. We conclude that the posterior paraventricular corona radiata region is most likely supplied by the AChA, and that AChA infarcts do not constitute a separate brain infarct entity.(ABSTRACT TRUNCATED AT 400 WORDS)

Aged↗
PubMed1989

Clinical distribution of anticentromere antibody in Japanese patients.

Serum samples from 401 subjects were screened for the presence of anticentromere antibody using HEp-2 cells as the substrate for an indirect immunofluorescence method. Anticentromere antibody was found in 16 cases; 8 out of 62 patients with systemic sclerosis, 3 out of 7 patients with primary Raynaud's disease, 2 out of 41 patients with systemic lupus erythematosus, 1 out of 54 asymptomatic relatives of systemic sclerosis and 2 out of 50 patients with miscellaneous diseases. In systemic sclerosis, the patients with anticentromere antibody were limited in CREST (calcinosis, Raynaud's phenomenon, esophageal involvement, sclerodactylia and telangiectasia) variant. As reported previously by many investigators, anticentromere antibody is considered as a useful immunologic marker for CREST variant of systemic sclerosis, although this antibody is widely distributed in other conditions with less frequency.

Autoantibodies↗
PubMed1997

Distributed clinical neurophysiology.

We have developed a consultation forum for clinical neurophysiology in Finland. The system connects local digital electroencephalography (EEG) recording and analysing networks using a high-speed asynchronous transfer mode (ATM) network. Clinicians can obtain a second opinion using interactive data and video consultations or using data-only consultations. In addition, the system can be used for off-line review of pre-recorded data. During a one-month evaluation, 66 EEG recordings were made altogether in Satakunta Central Hospital and consultations were required on 12 occasions. Nine of them were data-only consultations and three were data and video consultations. A data consultation lasted 15-20 min and a data and video consultation 35-45 min. Clinically, there were numerous benefits for the hospitals. The system established a link to a centre of excellence for second opinions or continuing education. It also helped with on-duty arrangements and enabled the construction of national data banks.

Electroencephalography↗
PubMed1983

Antibody to Ro in a population of patients with systemic lupus erythematosus: distribution, clinical and serological associations.

Anti-Ro occurs in 1/3 of systemic lupus erythematosus (SLE) patients with equal prevalence at all ages, ages at onset of SLE, and disease durations. In SLE anti-Ro is associated with xerophthalmia but not rheumatoid factor (RF). Anti ds-DNA rather than anti-Ro or RF is associated with SLE arthritis. We found a positive correlation between increased anti ds-DNA levels and the prevalence of anti-Ro in SLE patients' sera. This reinforces the thesis that anti-Ro may have considerable value as a diagnostic marker for SLE.

Adult↗
PubMed1997

Towards a component driven infrastructure for integrated healthcare systems.

A high level summarised description of the distributed clinical information system implemented in the hospital of the free university of Brussels (AZ-VUB) is described. It evolves towards a component based clinical distributed system that consists of a set of co-operating middelware software components running on a number of computers connected by a network that will foster the integration of applications, data servers and other resources in the medical field. This system is implemented in the University Hospital of Brussels (AZ-VUB) a full-service 800-bed university hospital that provides care for 23,000 inpatients, supports over 300,000 outpatient visits and receives 32,000 emergency patients a year.

Belgium↗
PubMed1986

Integrating clinical and distributive pharmaceutical services: implications for clinical pharmacy education.

For over two decades, pharmaceutical educators and practitioners have debated whether clinical and distributive pharmaceutical services should be integrated or segregated, i.e., performed by different persons. The recently defined new federal system for reimbursing hospitals for care of Medicaid patients and other beneficiaries according to a prospective reimbursement plan impacts directly on this debate. A cross section of the profession has recently reached consensus on the definition of clinical pharmacy at a national invitational workshop. Fiscal constraints also impacted on the question in schools which are no longer able to keep expanding their clinical faculties. These factors are related questions which academic clinical pharmacy must face are discussed.

Curriculum↗
PubMed1980

Patient-care unit system for measuring clinical and distributive pharmacy workload.

A time-weighted measurement of workload for distributive and clinical pharmaceutical services, the Patient-care Unit (PCU) System, is described. The Department of Pharmaceutical Services and the School of Pharmacy at the University of California, San Francisco, defines each patient-care pharmaceutical activity and assigns it a weighted value (WPCU) based on the time required to complete the activity. Manpower requirements are based on WPCUs and records of activities performed. Forty-two WPCUs have been defined. Based on these units, the PCU System permits (1) determination of pharmacy time devoted to distributive and clinical pharmaceutical services, (2) evaluation of staffing requirements for existing or proposed programs, (3) measurement of departmental productivity, and (4) comparison of pharmaceutical services offered in different hospitals. Applications and limitations of the PCU concept, which has been adopted by nine other hospitals, are discussed. The PCU System is a step toward development of a uniform workload reporting system for hospital pharmacies.

California↗
PubMed1975

Bioavailability studies and the clinical pharmacologist: correlation of drug distribution with clinical effects.

Bioavailability studies can be interpreted only when clinical information is available which correlates drug distribution with both efficacious and toxic clinical effects. The clinical pharmacologist should be instrumental in the development of safe and effective drug therapy by the systematic application of well designed clinical trials, the clear definition of therapeutically desirable clinical responses, and the development and application of improved techniques of measuring these effects.

Biological Availability↗